Marinomed announces global licensing partnership with Phargentis for Marinosolv® inhalation therapy
Marinomed signs term sheet with Phargentis SA for a worldwide exclusive license of the Marinosolv® technology platform for an inhalation formulation.
Partnership includes fee-for-service development, long-term milestone payments, and future royalties on product sales.
The collaboration leverages Marinomed’s expertise to enhance solubility and bioavailability of a specialized respiratory therapeutic.
Korneuburg, Austria, May 19th, 2026 – Marinomed Biotech AG (VSE:MARI), a dynamic biopharmaceutical company, today announced the signing of a term sheet with Phargentis SA. The term sheet contains the worldwide licensing of the proprietary Marinosolv® technology platform for the development of a high-performance formulation with a combination of different active pharmaceutical ingredients specifically designated for inhalation.
Under the terms of the agreement, Marinomed will provide specialized formulation services and technical expertise to develop a respiratory therapeutic utilizing the Marinosolv® platform. This technology is designed to significantly increase the solubility and bioavailability of hydrophobic compounds, enabling more effective delivery to the lungs and potentially reducing the required dosage for patients.
The financial structure of the partnership includes immediate fee-for-service components for the initial development phases. Furthermore, Marinomed is eligible to receive milestone payments tied to specific technical and clinical achievements throughout the development lifecycle, spanning several years. Upon successful commercialization, the agreement also stipulates the payment of royalties on net sales of the resulting product.
"This agreement marks another significant milestone in our strategy to monetize the Marinosolv® platform beyond our own internal pipeline," said Andreas Grassauer, CEO of Marinomed. "By applying our technology to inhalation therapies, we are addressing a critical need for better delivery of poorly soluble drugs in respiratory medicine. This partnership not only validates the versatility of our patent portfolio but also provides a sustainable revenue stream through services, milestones, and future royalties."
Expansion of Marinosolv® into inhalation therapies
The Marinosolv® technology has already demonstrated its capability in various ophthalmic and nasal applications. This latest expansion into inhalation underscores the platform’s potential to revolutionize treatment paradigms across multiple therapeutic areas where drug solubility remains a barrier to clinical success.
Contact
Marinomed Biotech AG
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: pr@marinomed.com
E-Mail: ir@marinomed.com